Target intelligence / Profile preview

Zinc finger protein Rlf (RLF)

Target
RLF
Molecular classification
Zinc finger protein (C2H2-type zinc finger family), Transcription factor
01

Overview

Zinc finger protein Rlf (RLF) is a human transcription factor encoded by the RLF gene, located on chromosome 1. It contains 15 C2H2-type zinc finger domains that enable DNA binding and activation of gene transcription, specifically through RNA polymerase II. RLF is closely related to ZNF292, sharing significant homology, especially at the N-terminus. Its biological roles include the regulation of transcription and chromatin structure, as well as protein-protein interactions through its zinc finger motifs. It has been implicated in cell maintenance, epigenetic regulation (hypomethylation of CpG shores at gene promoters), and disease processes such as cancer and neurodevelopmental disorders. RLF is localized to the nucleus but may also be present in extracellular exosomes. No drugs directly target RLF, and therapeutic modulation remains a technical challenge due to its molecular nature as a transcription factor.

Other names
ZNF292LZn-15LRearranged L-myc fusion gene proteinZn-15-related proteinZN-15Lzinc finger protein RlfZn-15 relatedrearranged L-myc fusion gene proteinrearranged L-myc fusion sequencezn-15-related proteinRLF
02

Mechanism of action

None currently annotated or described for this protein; in theory, mechanisms would involve modulation of DNA binding or protein-protein interactions, but such approaches have not reached clinical use

03

Biological functions

DNA bindingTranscriptional regulation (activator; RNA polymerase II-specific)Positive regulation of transcription by RNA polymerase IINegative regulation of heterochromatin formationProtein-protein interactionPotential roles in cell type maintenance and hypomethylation at gene promoters
04

Disease associations

Cancer (mutations or expression changes implicated)Neurodevelopmental disorders (e.g., autism spectrum disorder, ADHD, intellectual disability)Usher syndrome type IICLeft ventricular noncompaction
05

Safety considerations

Transcription factors like RLF are hard to target with small molecules due to lack of suitable ligand-binding pocketsGenome editing or oligonucleotide therapies could have off-target effects and challenge selectivity for RLF versus related zinc finger proteinsPotential impact on essential cellular functions if broadly inhibited (e.g., cell proliferation, gene expression)

Beyond the preview

Go deeper on Zinc finger protein Rlf (RLF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinc finger protein Rlf (RLF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call